Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail속도와 필요성: SARS-CoV-2 항체 칵테일에 대한 신속한 대응을 위한 두 가지 개발 과제Review Published on 2022-08-012022-09-12 Journal: Current opinion in biotechnology [Category] MERS, SARS, 비임상, 진단, [키워드] addressed antibody Cell culture Combined COVID-19 treatment Diseases example Genentech knowledge management monoclonal antibody monoclonal antibody treatment Patient Process provided purification rapid response Regeneron risk SARS-CoV-2 antibody selected speed timeline transfer Treatment urgency worldwide pandemic [DOI] 10.1016/j.copbio.2022.102715 PMC 바로가기 [Article Type] Review
Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal AntibodiesSARS-CoV-2 Omicron BA.1 및 BA.2 변이체의 백신 유도 혈청 및 치료용 단일클론 항체에 대한 내성Article Published on 2022-06-182022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] AstraZeneca BNT162b2 BNT162b2 vaccine COVID-19 D614G Effectiveness Emergency use fold immunization individual Lilly LY-CoV555 mixture monoclonal monoclonal antibodies monoclonal antibody monoclonal antibody therapy mutated neutralized Neutralizing titer omicron Omicron BA.2 Omicron variants parental Regeneron REGN10933 REGN10987 remained resistance SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants severe COVID-19 significantly Spike protein Spike proteins therapeutic therapy titer titers Vaccine variant variants virus [DOI] 10.3390/v14061334 PMC 바로가기 [Article Type] Article
Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2SARS-CoV-2의 오미크론 변이체에 대한 백신 보조제로서의 멜라토닌 및 REGN-CoV2 조합Review Published on 2022-05-012022-09-11 Journal: Molecular biology reports [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant adjuvant therapy affected antioxidant Antiviral caused cocktail Combination contagiousness coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 cytokine Cytokine storm delta variant develop elderly patients evaluate Immunocompromised immunomodulatory effects less mAb mAb cocktails mAbs melatonin multiple mutation multiple mutations Mutation neutralizing monoclonal antibodies neutralizing monoclonal antibody omicron Omicron variant Panic Prevent prevention of COVID-19 RBD Receptor binding domain Regeneron REGN-CoV2 respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe symptom shown Spike protein the spike protein therapy traction treat Treatment Vaccine variant of SARS-CoV-2 Viral viral invasion [DOI] 10.1007/s11033-022-07419-9 PMC 바로가기 [Article Type] Review
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies백신 유도 및 치료 항체에 의한 중화에 대한 SARS-CoV-2 Omicron 변이체의 내성 증가Article Published on 2022-04-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibody Antibody neutralization applied benefit BNT162b2 booster concern decrease disease severity Donor donors effective Effectiveness Efficacy Emergency use highlight immunization Increased incubated lentivirus Lilly luciferase luciferase activity luminometer maintain mapped Moderna monoclonal antibodies monoclonal antibody monoclonal antibody therapies monoclonal antibody therapy mutated neutralization Neutralizing NIH obstacle omicron Omicron variant Pfizer preventing infection PROTECT protein structure pseudotype pseudotyped lentiviruses Regeneron Resistance mutation resistance mutations SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV-2 variant sera serum Sotrovimab Spike protein T cells target cells the vaccine the vaccines therapeutic Therapies therapy titre Vaccine vaccine efficacy variant was measured [DOI] 10.1016/j.ebiom.2022.103944 PMC 바로가기 [Article Type] Article
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies감염성 SARS-CoV-2 B.1.1.529 Omicron 바이러스는 치료용 단일 클론 항체에 의한 중화를 피합니다Article Published on 2022-03-012022-09-11 Journal: Nature Medicine [Category] Fulltext, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected anti-receptor-binding domain antibody AstraZeneca B.1.1.529 Biotechnology Celltrion Clinical use Combination concerning coronavirus decrease Efficacy Lilly LY-CoV555 mAb mAbs monoclonal antibody Mutation neutralization neutralize Neutralizing activity omicron parent reduced Regeneron REGN10933 REGN10987 respiratory S309 SARS-CoV-2 severe acute respiratory syndrome Coronavirus Sotrovimab Spike protein tested the antibody the spike protein therapeutic TMPRSS2 TMPRSS2 cells variant Vero Vero-hACE2-TMPRSS2 cells Vir virus [DOI] 10.1038/s41591-021-01678-y PMC 바로가기 [Article Type] Article
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance오미크론 변이체(B.1.1.529): 감염성, 백신 돌파구 및 항체 내성Article Published on 2022-01-242022-09-11 Journal: Journal of Chemical Information and Modeling [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody resistance artificial intelligence AstraZeneca B.1.1.529 Celltrion Complete complexes contagious coronavirus delta variant determined by develop domain drug Drug administration Efficacy experimental results food GlaxoSmithKline Impact Infectivity likelihood Lilly mAb mAbs Mild monoclonal antibodies monoclonal antibody Mutation mutations omicron Panic Protein Quantitative analysis RBD Regeneron resistance respiratory response reveal SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant Structure the SARS-CoV-2 U.S. Food and Drug Administration university Vaccine Vaccines variant virus [DOI] 10.1021/acs.jcim.1c01451 PMC 바로가기 [Article Type] Article
Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement항 SARS-CoV-2 단일클론항체 요법 투여의 혜택을 받을 수 있는 소아 환자의 적격성 기준: 이탈리아 사회간 합의 선언문Review Published on 2022-01-122022-09-10 Journal: Italian Journal of Pediatrics [Category] 진단, 치료제, [키워드] administration adolescents Adult patients AIFA approved bamlanivimab benefit Casirivimab categories children clinician Comorbidities Comorbidity Consensus COVID19 criteria determinant determinants develop diffusion drug Eligible patients etesevimab Evolution favorable effect FDA food Food and Drug Administration Human Imdevimab increased risk indication indications Infection initial Italian Lilly mAb mAbs Medicine monoclonal antibody pandemic Patient Pediatric patient pediatrics produced progression Regeneron revision risk Risk factors SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic severe COVID-19 severe disease shown Society subject the SARS-CoV-2 therapeutic options therapy [DOI] 10.1186/s13052-021-01187-1 PMC 바로가기 [Article Type] Review
REGEN-COV ® antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantificationREGEN-COV ® 항체 칵테일 생물분석 전략: 약물 정량을 위한 LC-MRM-MS 및 면역분석 방법의 비교Comparative Study Published on 2021-12-012022-09-12 Journal: Bioanalysis [Category] MERS, SARS, 진단, [키워드] addition Analysis anti-SARS-CoV-2 antibody cocktail bioanalytical Bland-Altman Concentration correlation COVID-19 COVID-19 pandemic Critical dose drug drug concentration assay ECL immunoassay Initially linear monoclonal antibody monoclonal antibody therapeutic. parameters pharmacokinetic data produced profile public health emergency quantification REGEN-COV Regeneron Result SARS-CoV-2 supported targeted therapy therapeutic therapy USA was performed was used [DOI] 10.4155/bio-2021-0190 PMC 바로가기 [Article Type] Comparative Study
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistanceArticle Published on 2021-12-012022-10-28 Journal: ArXiv [Category] COVID-19, [키워드] acute respiratory syndrome antibody resistance antibody-resistance appear B.1.1.529 Celltrion Complete complexes contagious coronavirus COVID-19 delta variant domain drug Efficacy food Infectivity Lilly mAb mAbs Mild monoclonal antibody Mutation mutations omicron Panic Protein Quantitative analysis RBD Regeneron response reveal SARS-CoV-2 Structure the SARS-CoV-2 university Vaccine Vaccine breakthrough variant virus PMC 바로가기 [Article Type] Article
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple MyelomaConference abstract Published on 2021-11-232022-10-05 Journal: Blood [Category] 유전자 메커니즘, [키워드] addition Affect antibody Antibody Response Antibody titer Antigen AstraZeneca authors average Bayer Bluebird BMS board Cancer CAR Cell cellular immunity Characteristics conducted COVID COVID-19 COVID-19 antibody COVID-19 infection COVID-19 vaccination COVID-19 vaccine CRBN current Daichii Sankyo Debiopharm Deceased died download education eligible evaluated False positive figure for inclusion Frequency funding Genmab Glaxo healthy donors hematologic Hematologic malignancy humoral IgG antibody Immunocompromised Immunoglobulin immunologic response immunosuppressive individual Infection janssen life majority malignancies Mayo Clinic median medical records Mortality multicenter Multiple Multiple myeloma Myeloma national guideline NHL Non-Hodgkin Lymphoma offered Patent Patient Pfizer populations positive receive receptor recipient recipients Regeneron reported response Retrospective study SARS-CoV-2 Seattle Seroconversion seroconversion rate small sample size speaker submission survived T-cell tested the timing the vaccine Therapeutics therapy Treatment Trillium vaccination [DOI] 10.1182/blood-2021-151859 [Article Type] Conference abstract